PharmaResearch · 214450
PharmaResearch: Export Recovery, with Cash Conversion the Key
Analysis date
Published
As of 2026-10-22, the outlook for export growth is positive, but it is too early to be confident that the stock is undervalued. The quoted share price of KRW 252,500 represents approximately 15.1 times the recalculated diluted EPS reference figure, but declining profitability and slower cash collection must also be considered.
What this report covers
- Medical device and cosmetics exports drive growth
- Cash collection lags profit growth
- Assess overseas production expansion alongside investment costs
Sign in with Google to continue reading
You have read today's three free reports. You can reread them, or sign in to open another report.
The free reading limit resets at midnight Korea Standard Time.
New here? Signing in with Google also creates your account.
Sign in with Google to read the full report